natgillin/translations-raw huggingface dataset:
The second appendix 20 has a width approximately equal to that of the first seat 9 and a length less than the same, so as to be able to longitudinally move inside such first seat according to a desired path; advantageously the second appendix 20 has, in a longitudinal cross-section, an approximately oval shape and such second appendix 20 is transversally provided with a second through seat 21. 
Drugi nastavak 20 ima širinu približno jednaku širini prvog dosjeda 9 1 duljinu manju od duljine prvog dosjeda 9, tako da se on može pomaknuti uzdužno unutar tog prvog dosjeda prema željenoj stazi, pri čemu je korisno da drugi nastavak 20 ima u uzdužnom presjeku približno ovalan oblik i taj drugi nastavak 20 ima poprečno drugi prolazni dosjed 21.
In one embodiment, a subject has a % eosinophil in induced sputum of at least 0.1%, at least 0.5%, at least 1%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10% prior to the administration of the one or more doses of one or more IL-5R binding molecules. 
Protutijelo za uporabu prema bilo kojem od zahtjeva 1-4, naznačeno time da postoji smanjenje apsolutnog broja bazofila nakon davanja od barem 5, barem 10, barem 15, barem 20, barem 25, pri barem 30, barem 35, barem 40, najmanje 45, barem 50, barem 55, barem 60, barem 65 ili barem 70 bazofila/mm".
Therefore the presence or absence of serum in the starting material or crude harvest does not affect the binding the protein to a MEP HYPERCEL® column. 
Prema tome, prisutnost ili nedostatak seruma u polaznom materijalu ili sirovom prikupljenom materijalu ne utječe na vezanje protein na kolonu MEP HyperCel.
Preferably the compounds of the invention are considered useful for the treatment, prevention or alleviation of anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias including social phobias, obsessive-compulsive disorder, and generalized or substance-induced anxiety disorder; 
Spoj u skladu sa zahtjevom 7, naznačen time, što je bolest, poremećaj ili stanje depresija, kao što je panični poremećaj sa ili bez agorafobije, agorafobija bez povijesti paničnog poremećaja, strah od životinja i druge fobije, društvena fobija, opsesivno-kompulzivni poremećaj i opći ili posebni poremećaj uslijed depresije. t>&
A lead-free solder alloy having an alloy composition which contains 31 to 59 mass % of Bi, 0.3 to 1.0 mass % of Cu, 0.01 to 0.06 mass % of Ni and balance of Sn. The lead-free solder alloy according to Claim 1, further containing at least one element selected from a group consisting of P and Ge in a total of 0.003 to 0.05 mass %. 
Legura za lemljenje bez olova prema zahtjevu 1, naznačena time da se sastoji od 31 do 59 masenih % Bi, 0.3 do 1.0 masenih % Cu, 0.01 do 0.06 masenih % Ni, i barem jedan element koji je odabran iz skupine koju čine Pi Ge u ukupnom iznosu od 0.003 do 0.05 masenih %, i ravnotežni udio $n.
wherein in compound of formula (I), 
R! gdje kod spoja formule (I)
In addition, this invention provides a compound of Formulas I or II, or a pharmaceutically acceptable salt thereof for use in the treatment of type 2 diabetes. 
Spoj, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 5, u liječenju dijabetesa tip 2.
preparing the compound of Formula IIa: by a process comprising reacting a compound of Formula IIc: with prop-2-en-1-ol in the presence of a palladium catalyst and a base; 
Ila postupkom koji obuhvaća reakciju spoja s formulom IIc: N lIc S prop-2-en-1-olom u prisutnosti paladijevog katalizatora i baze; pri čemu X; je klor, brom, ili jod, ili
A method for inhibiting VR1 function in a cell in vitro comprising contacting a cell, capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 or claim 20. 
Postupak za inhibiranje VRI funkcije u stanici in vitro naznačen time da sadrži kontaktiranje stanice, koja može izražavati VRI1, sa učinkovitom količinom spoja ili farmaceutski prihvatljivo soli spoja prema zahtjevu 1 ili zahtjevu 20.
This publication cites US-BS 6,341,504 . 
Ta publikacija navodi US-BS 6,341,504.
The pharmaceutical composition according to claim 7, wherein the cardiac condition is cardiac arrhythmia, tachycardia, atrial arrhythmia, atrial tachyarrhythmia, atrial fibrillation, sustained atrial fibrillation, non-sustained atrial fibrillation, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sustained ventricular tachycardia, non-sustained ventricular tachycardia, catecholaminergic polymorphic ventricular tachycardia (CPVT), heart failure, sudden cardiac death or exercise-induced sudden cardiac death. 
Farmaceutska kompozicija prema patentnom zahtjevu 7, naznačena time što je srčano stanje srčana aritmija, tahikardija, atrijalna aritmija, atrijalna tahiaritmija, atrijalna fibrilacija, dugotrajna atrijalna fibrilacija, kratkotrajna atrijalna fibrilacija, ventrikularna artimija, ventrikularna fibrilacija, ventrikularna tahikardija, dugotrajna ventrikularna tahikardija, kratkotrajna ventrikularna tahikardija, kateholaminergička polimorfna ventrikularna tahikardija (CPVT), srčana insuficijencija, iznenadna srčana smrt ili iznenadna srčana smrt izazvana pojačanom fizičkom aktivnošću.
A compound according to claim 6, wherein A is optionally substituted pyridyl, optionally substituted benzofuranyl, optionally substituted 3H-isobenzofuran-1-on-yl or optionally substituted 2,3-dihydro-isoindol-1-on-yl. 
Spoj prema zahtjevu 6, naznačen time da je A po izboru supstituirani piridil, po izboru supstituirani benzofuranil, po izboru supstituirani 3H-izobenzofuran-1-on-il ili po izboru supstituirani 2,3-dihidro-izoindol-1-on-il.
A compound of formula (I) according to claim 1 wherein R3 is a methyl group substituted with an aryl (substituted or unsubstituted), and R1, R2, and R4 are as described in claim 1. 
Spoj s formulom (D prema zahtjevu 1 naznačen time da Rs je metilna skupina supstituirana s arilom (supstituiranim ili nesupstituiranim), i R;, R2, i Ry su kako je opisano u zahtjevu 1.
Then the container is pushed down spreading the segment of the rosette and falling to the bottom of the housing. 
Zatim se spremnik gurne dolje, pri čemu se segmenti rozete rašire i on padne na dno kućišta.
The monoclonal antibody or a functional fragment of the monoclonal antibody according to any one of claims 1 to 4 which inhibits osteoclastic bone resorption. 
Monoklonsko antitijelo ili njegov funkcionalni fragment, sukladno sa bilo kojim od zahtjeva 1-4, koji inhibiraju osteoklastnu resorpciju kostiju.
r is zero, 1 or 2, wherein in case m is zero then r is zero; 
r je nula, 1 ili 2, dok u slučaju da je m jednak nuli, r je nula;
a cutting edge portion (112) at a distal end of the shaft, wherein the cutting edge portion comprises at least a first and a second bend (102,104) and a distal end point (106); 
- < odsječak Trezne oštrice (112) na distalnom kraju osovine, pri čemu odsječak rezne oštrice sadrži najmanje prvi i drugi savijeni dio (102, 104) i točku distalnog kraja (106);
administration of a vaccine booster composition to the subject 6 or 12 months after the primary immunization schedule is completed, the vaccine booster composition comprising a pharmaceutically effective carrier, about 1 mg of a peptide having the amino acid sequence SEQ ID NO:2, and about 0.125 to 0.250mg of human granulocyte-macrophage colony stimulating factor. 
(1i) pripravak booster cjepiva koji sadrži 1 mg peptida koji sadrži sekvencu amino kiseline SEQ ID NO:2, 1 0.125 ili 0.250 mg humanog stimulirajućeg faktora kolonije granulocita/makrofaga (GM-CSF) kao adjuvanta, pri čemu je pripravak booster cjepiva formuliran za davanje pomoću injekcije, poželjno intradermalne injekcije, svakih šest mjeseci nakon završetka primarne imunizacije.
A transporter cargo conjugate molecule or a pharmaceutical composition comprising a transporter cargo conjugate or a vaccine comprising a transporter cargo conjugate molecule for use according to claim 15, wherein the disease and/or disorder involving white blood cells is selected from: selected from cancer or tumor diseases, including diseases caused by defective apoptosis; inflammatory diseases, infectious diseases including bacterial and viral (infectious) diseases, diseases strongly related to JNK signalling, autoimmune disorders or diseases, cardiovascular diseases, neuronal or neurodegenerative diseases, diseases of the liver, diseases of the spine, diseases of the uterus, major depressive disorders, non-chronic or chronic inflammatory digestive diseases, diabetes, hair loss, hearing loss or diseases of the inner ear. 
Uporaba transporterske teretne konjugirane molekule prema bilo kojem od zahtjeva 7 do 9 naznačena time da je za pripremu lijeka za sprječavanje, liječenje i/ili ublažavanje raka ili tumorskih bolesti, uključujući bolesti izazvane neispravnom apoptozom, upalne bolesti, infektivne bolesti, virusne (infektivne) bolesti, bolesti snažno povezane sa JNK signalizacijom, autoimune poremećaje ili bolesti, kardiovaskularne bolesti, neuronske ili neurodegenerativne bolesti, bolesti jetre, bolesti kralježnice, bolesti maternice, velike depresivne poremećaje, ne-kronične ili kronične upalne probavne bolesti, gubitak sluha, bolesti unutrašnjeg uha, ili za uporabu kod transplantacije tkiva.
An isolated antigen presenting cell transfected with a nucleic acid molecule consisting of a nucleotide sequence encoding a polypeptide comprising a sequence selected from the group consisting of: SEQ ID NO: 1; 
Molekula nukleinske kiseline za primjenu u medicini gdje molekula nukleinske kiseline se sastoji od sekvence nukleinske kiseline koja kodira polipeptid koji sadrži sekvencu odabranu iz grupe koja se sastoji od: SEQ.
The following abbreviations are used: 
Korištene su slijedeće skraćenice:
A kit comprising the combination of any one of claims 1 to 8 for use in reducing elevated intraocular pressure in an eye of a subject. 
Komplet za uporabu iz bilo kojeg od patentnih zahtjeva 1 do 8 za uporabu u smanjivanju povišenog intraokularnog tlaka u oku subjekta.
cutting the supporting sheet (5) at marginal border of the decorative bodies (2) in such a way that perimetric edge (13) of the supporting sheet follows the ornamental shape defined by the arrangement of the decorative bodies (2), said cutting step being a laser cutting. 
- < rezanje potpornog lista (5) na granici dekorativnih tijela (2) na način da perimetrijski rub (13) potpornog lista prati ornamentalni oblik definiran dekorativnim tijelima (2), navedeni korak rezanja provodi se pomoću lasera.
A compound according to Claim 1 wherein R1 is chloro or trifluoromethoxy and R2 is hydrogen or chloro; or a pharmaceutically acceptable salt or enantiomer thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je klor ili trifluormetoksi, a R2 je vodik ili klor; ili njegova farmaceutski prihvatljiva sol ili enantiomer.
According to an embodiment, the composition for use according to any of claims 1 to 2, wherein the concentration of lactic acid, or the concentration of lactate ion of the pharmaceutically acceptable salt, in the composition is at least 12 mmol/L, for example within the range of from 12 to 12000 mmol/L, such as from 100 to 10000 mmol/L, such as from 500 to 5000 mmol/L, such as from 800 to 2000 mmol/L. 
Kompozicija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačena time što je koncentracija mliječne kiseline ili koncentracija iona laktata farmaceutski prihvatljive soli, u kompoziciji najmanje 12 mmol/L, na primjer unutar opsega od 12 do 12000 mmol/L, kao što je od 100 do 10000 mmol/L, kao što je od 500 do 5000 mmol/L, kao što je od 800 do 2000 mmol/L.
In a fourth step of the method, the sinkers 33 are disengaged from the manufacture so that the manufacture, due to the upward thrust, moves with the loops of its last row of knitting 80 into the upper head 9 a of the needles 8 (FIG. 11). 
- > četvrti korak, koji se sastoji od odvajanja platina (33) od proizvoda te se navedeni proizvod, zbog potiskivanja naviše, pomiče tako da su petlje zadnjeg reda pletiva (80) u gornjim glavama (94) igala (8);
The method according to claim 5, wherein the crystallization solvent is preferably a mixed solvent of ethanol/water, and the anti-solvent is ethanol. 
Postupak sukladno zahtjevu 6, naznačen time što je otapalo za kristalizaciju poželjno miješano otapalo etanol / voda, a protu-otapalo etanol.
is as defined above and n2 is an integer from 0 to 2; wherein: n1, n2, R2 and X1 are as defined above; 
(OR*),» gdje: n' je kao što je gore definiran, a n? je cijeli broj od 0 do 2, X; = ili te R* jest H ili CH,
The conjugate for the use of claim 9, wherein the method is of treating cancer of the lung, breast, colon, prostate, kidney, pancreas, ovary, or lymphatic organs. 
Konjugat za uporabu prema zahtjevu 24, gdje je postupak liječenje raka pluća, dojke, debelog crijeva, prostate, bubrega, gušterače, jajnika ili limfnih organa.
The pharmaceutically acceptable acid addition salts of the free bases of the invention are prepared by simply treating the free bases with various mineral and organic acids which form non-toxic acid addition salts, such as the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, maleate, fumarate, citrate, acid citrate, tartrate, bitartrate, succinate, gluconate and saccharate salts. 
Farmaceutski prihvatljive aditivne soli s kiselinama slobodnih baza iz izuma prave se jednostavnim tretiranjem slobodnih baza s raznim mineralnim i organskim kiselinama koje formiraju netoksične aditivne soli s kiselinama, kao što su klorhidratne, bromhidratne, jodhidratne, sulfatne, bisulfatne, fosfatne, bifosfatne, acetatne, laktatne, maleatne, fumaratne, citratne, kiseline citratne, tetraratne, bitartaratne, sukcinatne, glukonatne i saharatne soli.
A process for preparing a compound of formula (I): and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, wherein Q represents NR3R4, R1 represents hydrogen or C1-4 alkyl group, R2 represents hydrogen or C1-4 alkyl group, R3 represents hydrogen, C1-4 alkyl group, phenyl or optionally substituted phenyl, R4 represents hydrogen, C1-4 alkyl group, phenyl or optionally substituted phenyl, wherein the term "optionally substituted phenyl" means a phenyl group which can be substituted in any position by one or more halogen, C1-4 alkyl, C1-4 alkoxy, trifluoromethyl and/or cyano group, or combinations thereof comprising reacting an isocyanate of formula (IV): 
R" predstavlja vodik ili C,4 alkil skupinu, R* predstavlja vodik, C,. alkil skupinu, fenil ili opcijski supstituirani fenil, R* predstavlja vodik, C,., alkil skupinu, fenil ili opcijski supstituirani fenil, gdje izraz "opcijski supstituirani fenil? znači fenilna skupina koja može biti supstituirana na bilo kojoj poziciji s jednom ili više halogen, C,4 alkil, C,4 alkoksi, trifluorometil i/ili cijano skupinom, ili njihovim kombinacijama, pri čemu postupak obuhvaća reakciju izocijanata formule (IV):
The dried granules were sieved through mesh #20 and blended with a lubricants comprising of 26.45 mg (12.43% w/w) of microcrystalline cellulose, 0.575 mg (0.27% w/w) of colloidal silicon dioxide and 1.15 mg (0.54% w/w) of magnesium stearate previously sieved through mesh #60. 
Osušene granule prosijane su kroz sito # 20 te pomiješane s lubrikantom koji je sadržavao 26,45 mg (12,43 % w/w) mikrokristalne celuloze, 0,575 mg (0,27 % w/w) koloidnog silicij dioksida 1 1,15 mg (0,54 % w/w) magnezij stcarata, prethodno prosijanih kroz sito # 60.
said carbonate base is selected from the group consisting of LiHCO3, NaHCO3, KHCO3, L12CO3, Na2CO3, and K2CO3. The process of any one of claims 2 to 5, wherein said biphasic solvent system comprises water and a water-immiscible solvent. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedenu karbonatnu bazu se bira iz skupine koju čine LiHCO»s, NaHCO,, KHCOÂ«4, Lib>CO»s, NaC03 i K2COs.
Use of a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer. 
Uporaba polipeptida koji sadrži vanstanične IPT-3 i IPT-4 domene receptora faktora rasta hepatocita za pretraživanje farmakološki aktivnih tvari korisnih za liječenje raka.
Next, 100µL of 1M TBAF in THF was charged to the flask and the reaction was stirred at room temperature for 1 hour; the reaction was monitored by TLC and/or HPLC for disappearance of starting material. 
Zatim je bilo stavljeno 100 mL IM TBAF u tikvicu i rcakcijska smjesa je bila miješana na sobnoj temperaturi kroz 1 sat; reakcija je bila nadzirana pomoću TLC i/li HPLC radi nestajanja početnog materijala.
iv) at least one oligonucleotide comprising or consisting essentially of a sequence selected from the group consisting of SEQ ID NO: 4, 31-42, SEQ ID NO: 8, 58-61, SEQ ID NO: 83 or 84, wherein said one or more oligonucleotides are suitable for use as probes and/or at least one oligonucleotide combination comprising or consisting essentially of either the sequences of SEQ ID NO: 77 and 78, of SEQ ID NO: 79 and 80, of SEQ ID NO: 81 and B2, of SEQ ID NO: 102 and 103, or of SEQ ID NO: 104 and 105, wherein said one or more oligonucleotide combinations are suitable for use as probe combinations; and 
Postupak za analizu metilacije koji obuhvaća a) tretiranje genomske cDNA s jednim ili više reagensa kako bi se prevelo nemetilirane citozinske baze u uracil sulfonat ili u drugu bazu koja se ponaša drugačije pri vezanju od citozina, dok metilirani citozin ostaje nepromijenjen; b) amplificiranje tretirane DNA pomoću i) oligonukleotida koji obuhvaća ili sadrži sekvencu definiranu SEQ ID NO: 5 ili njegova varijanta s 5'- terminalnim i/ili 3'-terminalnim izbacivanjem I, 2, 3, 4 ili 5 nukleotida; i ii) oligonukleotida koji obuhvaća ili sadrži sekvencu definiranu SEQ ID NO: 44 ili njegova varijanta s 5'- terminalnim i/ili 3'-terminalnim izbacivanjem 1, 2, 3, 4 ili 5 nukleotida; pri čemu navedeni oligonukleotidi su prikladni za uporabu kao primeri;
The method of claim 7, wherein said first capture antibody specifically binding to the non-cleaved and Neurotoxin-cleaved substrate is the rabbit polyclonal anti-SNAP-25 antibody S9684, the rabbit polyclonal anit-SNAP25 antibody PA5-19708 (Pierce Antibodies), or the rabbit polyclonal anti-SNAP25 antibody PA5-19701 (Pierce Antibodies). 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što je navedeno prvo hvatačko protutijelo koje se specifično veže na necijepani i neurotoksinom cijepani supstrat kunićje poliklonsko protutijelo S9684 protiv SNAP-25, kunićje poliklonsko protutijelo PA5-19708 (Pierce Antibodies) protiv SNAP25, ili kunićje poliklonsko protutijelo PA5-19701 (Pierce Antibodies) protiv SNAP25.
The method of claim 14, wherein the Crenolanib or a salt thereof is provided as a single agent or in combination with another chemotherapeutic agent for treatment of pediatric patient with the hematologic malignant neoplastic disorder. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 13, pri čemu se crenolanib ili njegova sol osigurava kao jedini agens ili u kombinaciji s drugim kemoterapijskim agensom za liječenje pedijatrijskog subjekta s akutnom mijeloičnom leukemijom (AML).
n represents 0 to 3; m represents 0 to 1 and o represents 1 to 2. 
n predstavlja 0 do 3; m predstavlja 0 do 1; i o predstavlja 1 do 2.
The use according to any one of the preceding claims wherein the daily dosage is raised stepwise up to 6 times up to the standard daily dosage and thereafter the treatment is continued with the standard dailydosage. 
Uporaba prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, što se dnevna doza postepeno povišava do 6 puta, do standardne dnevne doze, a nakon toga se liječenje nastavlja standardnom dnevnom dozom.
In another embodiment, said first base is selected from the group consisting of triethylamine, 1,5-diazabicyclo[4,3,0]non-5-ene 1,4-diazabicyclo[2,2,2]octane, and 1,8-diazabicyclo[5,4,0]undec-7-ene, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedenu prvu bazu se bira iz skupine koju čine trietilamin, 1,5-diazabiciklo[4.3.0]non-5-en, 1,4-diazabiciklo[2.2.2]oktan i 1,8-diazabiciklo[5.4.Q0]undec-7-en, te smjese 2 ili više njih.
reducing the current flowing in the active load (50) to a holding current (IH) at the end of the validation of the candidate signal (Sc), and characterized in that it further comprises: 
- - slabljenju struje koja ide u aktivni teret (50) do struje držanja (Ig) na kraju provjere kandidatnog signala (S.), te što se dodatno sastoji u:
The thermoplastic film according to claim 1, wherein the ratio of the average width to the average length of said elements of the current invention is in the range.of 1:500-1:10,000,000, preferably in the range of 1:50-1:500,000. 
Termoplastična folija sukladno zahtjevu 1, pri čemu omjer prosječne širine u odnosu na prosječnu duljinu elemenata navedenog izuma iznosi 1:500-1:10,000,000, poželjno opsega 1:50-1:500,000.
As alternative to this, it has been shown in practice that the filling medium can be removed from the groove structures 4 of the separated nozzle arrangements 1 by dissolving the filling medium in a solvent and by sparging the filling medium/solvent mixture if necessary. 
Kao alternativa tome, iz prakse se zna da se punilo može odstraniti iz brazdastih struktura 4 odvojenih naprava 1 s mlaznicom otapanjem punila u otapalu i prema potrebi propuhivanjem mješavine punila i otapala.
The nucleic acid of any one of the preceding claims, further comprising a regulatory element and a leader sequence operably linked to the nucleotide sequence. 
Miš iz bilo kojeg zahtjeva 9. – 11. pri čemu je nukleotidni slijed operabilno povezan s endogenim regulatornim elementima miša.
The thermoplastic film according to claim 10, wherein each of the fibres covers an area of the base film of more than 8.0 mm2. 
Termoplastična folija sukladno bilo kojem od prethodnih zahtjeva, pri čemu svako od vlakana pokriva površinu veću od 4.
The process according to claim 11 wherein said lipase from Candida is present in an amount ranging from about 1,000 to 1,000,000 U/mmol when the lipase from Candida is Candida cylindracea, and from about 100 to 100,000 U/mmol when the lipase from Candida is Candida antarctica of type B. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što je navedena lipaza iz Candida prisutna u rasponu količina od otprilike 1.000 do 1.000.000 U/mmol za kvasac Candida cilindracea (CCL), te u rasponu od otprilike 100 do 100.000 U/mmol za kvasac Candida antartica tipa B (CALB).
The pharmaceutical composition according to claim 1, wherein the at least one water-soluble polymer is copovidone. The pharmaceutical composition according to claim 1, wherein the at least one water-soluble polymer is sodium starch glycolate. The pharmaceutical composition according to claim 1, wherein the at least one water-soluble polymer is croscarmellose sodium, homopolymers and copolymers of N-vinyl lactams, polyethylene oxide, polypropylene oxide, copolymers of ethylene oxide and propylene oxide, polyacrylates, polymethacrylates, polyacrylamides, vinyl acetate polymers, polyvinyl alcohol, carrageenans, cellulose esters, cellulose ethers, cellulose succinates, or combinations thereof. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što pripravak sadrži umreženu karboksimetilceluozu-natrij i/ili homopolimere i kopolimere N-vinillaktama i/ili polietilen-oksida i/ili polipropilen-oksida i/ili kopolimere etilen-oksida i propilen-oksida i/ili poliakrilate i/ili polimetakrilate i/ili poliakrilamide/ili vinil-acetatne polimere i/ili polivinil-alkohol i/ili karagenane i/ili celulozne estere i/ili celulozne etere i/ili celulozne sukcinate kao polimere topljive u vodi.